{"generic":"Verapamil Hydrochloride","drugs":["Calan","Calan SR","Covera-HS","Isoptin SR","Verapamil Hydrochloride","Verelan","Verelan PM"],"mono":{"0":{"id":"653400-s-0","title":"Generic Names","mono":"Verapamil Hydrochloride"},"1":{"id":"653400-s-1","title":"Dosing and Indications","sub":[{"id":"653400-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Atrial fibrillation and flutter:<\/b> (IV) initial, 5 to 10 mg (0.075 to 0.15 mg\/kg) IV over at least 2 minutes under continuous ECG and blood pressure monitoring; may give additional 10 mg after 30 minutes if inadequate response<\/li><li><b>Atrial fibrillation and flutter:<\/b> (oral, immediate-release tablets) initial, 240 to 320 mg ORALLY daily in 3 to 4 divided doses in digitalized patients; MAX dose 480 mg\/day<\/li><li><b>Hypertension:<\/b> (immediate-release tablet) initial, 80 mg ORALLY 3 times daily; titrate based on response; no evidence of added effect with total daily doses greater than 360 mg; MAX dose 480 mg\/day<\/li><li><b>Hypertension:<\/b> (sustained-release caplet (Calan(R) SR) or tablet (Isoptin(R) SR)) initial, 180 mg ORALLY once daily in the morning; may titrate dose up to 240 mg ORALLY every 12 hours at weekly intervals based on response 24 hours after dosing<\/li><li><b>Hypertension:<\/b> (sustained-release capsule (Verelan(R))) usual dose, 240 mg ORALLY once daily in the morning; may titrate dose up to 480 mg ORALLY once daily in the morning based on response 24 hours after dosing<\/li><li><b>Hypertension:<\/b> (extended-release capsule (Verelan(R) PM)) initial, 200 mg ORALLY once daily at bedtime; may titrate up to 400 mg ORALLY once daily at bedtime<\/li><li><b>Hypertension:<\/b> (extended-release tablet (Covera-HS(R)) initial, 180 mg ORALLY once daily at bedtime; may titrate up to 480 mg ORALLY once daily at bedtime<\/li><li><b>Migraine; Prophylaxis:<\/b> 80 mg ORALLY 3-4 times daily<\/li><li><b>Paroxysmal supraventricular tachycardia:<\/b> (IV) initial, 5 to 10 mg (0.075 to 0.15 mg\/kg) IV over at least 2 minutes (3 minutes for elderly patients) under continuous ECG and blood pressure monitoring; may give additional 10 mg after 30 minutes if inadequate response<\/li><li><b>Paroxysmal supraventricular tachycardia; Prophylaxis:<\/b> (immediate-release tablets) 240 to 480 mg daily in 3 to 4 divided doses; MAX dose 480 mg\/day<\/li><li><b>Stable angina, chronic:<\/b> (immediate-release tablets) 80 to 120 mg ORALLY 3 times daily; may titrate at daily or weekly intervals based on response 8 hours after dosing; MAX dose 480 mg<\/li><li><b>Stable angina, chronic:<\/b> (extended-release tablets (Covera-HS(R)) initial, 180 mg ORALLY once daily at bedtime; may titrate up to 480 mg ORALLY once daily at bedtime<\/li><li><b>Unstable angina:<\/b> (immediate-release tablets) 80 to 120 mg ORALLY 3 times daily; may titrate at daily or weekly intervals based on response 8 hours after dosing; MAX dose 480 mg<\/li><li><b>Variant angina:<\/b> (immediate-release tablets) 80 to 120 mg ORALLY 3 times daily; may titrate at daily or weekly intervals based on response 8 hours after dosing; MAX dose 480 mg<\/li><\/ul>"},{"id":"653400-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Atrial fibrillation and flutter:<\/b> (IV, less than 1 year old) initial, 0.1 to 0.2 mg\/kg IV bolus over at least 2 minutes under continuous ECG and blood pressure monitoring; may repeat dose after 30 minutes if initial dose inadequate<\/li><li><b>Atrial fibrillation and flutter:<\/b> (IV, 1 to 15 years old) initial, 0.1 to 0.3 mg\/kg IV over at least 2 minutes under continuous ECG and blood pressure monitoring (MAX dose 5 mg); may repeat dose after 30 minutes if initial dose inadequate (MAX dose 10 mg)<\/li><li><b>Atrial fibrillation and flutter:<\/b> (oral) 4 to 10 mg\/kg\/day divided 3 times daily<\/li><li><b>Hypertension:<\/b> initial dose, 3 mg\/kg ORALLY in 3 divided doses; usual dose, 3 to 4 mg\/kg ORALLY in 3 divided doses; MAX 8 mg\/kg up to 480 mg daily in 3 divided doses (Flynn &amp; Pasko, 2000)<\/li><li><b>Paroxysmal supraventricular tachycardia:<\/b> (less than 1 year old) initial, 0.1 to 0.2 mg\/kg IV bolus over at least 2 minutes under continuous ECG and blood pressure monitoring; may repeat dose after 30 minutes if initial dose inadequate<\/li><li><b>Paroxysmal supraventricular tachycardia:<\/b> (1 to 15 years old) initial, 0.1 to 0.3 mg\/kg IV over at least 2 minutes under continuous ECG and blood pressure monitoring (MAX dose 5 mg); may repeat dose after 30 minutes if initial dose inadequate (MAX dose 10 mg)<\/li><li><b>Supraventricular tachycardia:<\/b> 1 to 3 mg\/kg every 8 hours is recommended.<\/li><\/ul>"},{"id":"653400-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Dialysis:<\/b> no dose adjustments are needed (Aronoff et al, 1999)<\/li><li><b>liver disease:<\/b> 20% to 50% of normal dose; consider reducing Verelan(R) PM initial dose to 100 mg orally once daily at bedtime<\/li><li><b>geriatrics (hypertension, angina):<\/b> decrease initial doses to 40 mg 3 times daily for immediate-release tablets, 120 mg once daily for Calan(R) SR, Verelan(R), or Isoptin(R) SR, and 100 mg once daily at bedtime for Verelan(R) PM; use the lower end of the dosing range for Covera-HS(R); administer IV doses over at least 3 minutes<\/li><li><b>low-weight patients (hypertension, angina):<\/b> decrease initial doses to 40 mg 3 times daily for immediate-release tablets, 120 mg once daily for Calan(R) SR, Verelan(R), or Isoptin(R) SR, and 100 mg once daily at bedtime for Verelan(R) PM<\/li><li><b>renal impairment:<\/b> no dosage adjustment is recommended in patients with any degree of renal failure; consider reducing Verelan(R) PM initial dose to 100 mg orally once daily at bedtime; if repeat IV doses are needed, give smaller doses<\/li><\/ul>"},{"id":"653400-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Atrial fibrillation and flutter<\/li><li>Hypertension<\/li><li>Paroxysmal supraventricular tachycardia<\/li><li>Paroxysmal supraventricular tachycardia; Prophylaxis<\/li><li>Stable angina, chronic<\/li><li>Unstable angina<\/li><li>Variant angina<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Cluster headache<\/li><li>Coronary arteriosclerosis<\/li><li>Electroconvulsive therapy<\/li><li>Hypertrophic cardiomyopathy<\/li><li>Keloid scar<\/li><li>Kidney disease<\/li><li>Migraine; Prophylaxis<\/li><li>Spasm of cerebral arteries - Subarachnoid hemorrhage<\/li><li>Supraventricular tachycardia<\/li><\/ul>"}]},"3":{"id":"653400-s-3","title":"Contraindications\/Warnings","sub":[{"id":"653400-s-3-9","title":"Contraindications","mono":"<ul><li>atrial fibrillation\/flutter associated with accessory bypass tract (eg, Wolff-Parkinson-White, Lown-Ganong-Levine)<\/li><li>cardiogenic shock<\/li><li>hypersensitivity to verapamil hydrochloride (Calan(R))<\/li><li>hypotension (less than 90 mmHg systolic pressure)<\/li><li>left ventricular dysfunction, severe (ejection fraction less than 30%)<\/li><li>second- or third-degree atrioventricular block (without functioning artificial pacemaker)<\/li><li>sick sinus syndrome (without functioning artificial pacemaker)<\/li><\/ul>"},{"id":"653400-s-3-10","title":"Precautions","mono":"<ul><li>concomitant use of a beta-adrenergic blocker in patients with any degree of ventricular dysfunction should be avoided<\/li><li>concomitant use of quinidine in patients with hypotrophic cardiomyopathy should be avoided<\/li><li>congestive heart failure may occur<\/li><li>Duchenne muscular dystrophy; decreased neuromuscular transmission; consider dose reduction (Calan (R))<\/li><li>elevated liver enzymes, particularly serum transaminase levels, have been reported; hepatocellular injury may occur; monitoring recommended<\/li><li>first-degree atrioventricular block, marked, or progression to second- or third-degree block may occur; dose reduction or discontinuation may be necessary<\/li><li>hepatic function impairment; consider dose reduction and monitoring<\/li><li>hypertrophic cardiomyopathy; sinus bradycardia, pulmonary edema, severe hypotension, second-degree AV block, sinus arrest, and death have been reported in these patients<\/li><li>hypotension and\/or dizziness may occur<\/li><li>myasthenia gravis; worsening of condition; consider dose reduction (Calan(R))<\/li><li>neuromuscular transmission defects (eg, Duchenne muscular dystrophy); may result in respiratory depression<\/li><li>pulmonary edema may occur<\/li><li>renal function impairment; monitoring for prolongation of PR interval or other signs of overdose<\/li><li>report suspected adverse reactions to the US Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"653400-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Verapamil: C (FDA)<\/li><li>Verapamil: C (AUS)<\/li><\/ul>"},{"id":"653400-s-3-12","title":"Breast Feeding","mono":"<ul><li>Verapamil: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Verapamil: WHO: Compatible with breastfeeding.<\/li><li>Verapamil: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"653400-s-4","title":"Drug Interactions","sub":[{"id":"653400-s-4-13","title":"Contraindicated","mono":"<ul><li>Colchicine (established)<\/li><li>Dofetilide (probable)<\/li><li>Lomitapide (theoretical)<\/li><\/ul>"},{"id":"653400-s-4-14","title":"Major","mono":"<ul><li>Acebutolol (probable)<\/li><li>Adenosine (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Alprenolol (probable)<\/li><li>Amiodarone (probable)<\/li><li>Apixaban (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Atenolol (probable)<\/li><li>Atorvastatin (theoretical)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bosutinib (theoretical)<\/li><li>Bucindolol (probable)<\/li><li>Bupivacaine (probable)<\/li><li>Bupivacaine Liposome (probable)<\/li><li>Carbamazepine (theoretical)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Clarithromycin (established)<\/li><li>Clonidine (probable)<\/li><li>Clopidogrel (theoretical)<\/li><li>Clozapine (established)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabigatran Etexilate (established)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dantrolene (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Digoxin (established)<\/li><li>Dilevalol (probable)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dronedarone (probable)<\/li><li>Eliglustat (theoretical)<\/li><li>Eplerenone (probable)<\/li><li>Erlotinib (theoretical)<\/li><li>Erythromycin (probable)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Esmolol (probable)<\/li><li>Everolimus (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Ibrutinib (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Labetalol (probable)<\/li><li>Lacosamide (theoretical)<\/li><li>Levobunolol (probable)<\/li><li>Lovastatin (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Mepindolol (probable)<\/li><li>Mepivacaine (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metoprolol (probable)<\/li><li>Mitotane (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Nadolol (probable)<\/li><li>Naloxegol (theoretical)<\/li><li>Nebivolol (probable)<\/li><li>Nilotinib (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Oxprenolol (probable)<\/li><li>Paritaprevir (theoretical)<\/li><li>Penbutolol (probable)<\/li><li>Pindolol (probable)<\/li><li>Piperaquine (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Propranolol (probable)<\/li><li>Ranolazine (probable)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Simvastatin (established)<\/li><li>Sotalol (probable)<\/li><li>Talinolol (probable)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><\/ul>"},{"id":"653400-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Buspirone (probable)<\/li><li>Celecoxib (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Clonixin (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Dalfopristin (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Digitoxin (probable)<\/li><li>Dipyrone (probable)<\/li><li>Dutasteride (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Flecainide (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Indinavir (probable)<\/li><li>Indomethacin (probable)<\/li><li>Itraconazole (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lithium (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Midazolam (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Nevirapine (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxcarbazepine (established)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Pancuronium (probable)<\/li><li>Parecoxib (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Phenytoin (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Quinidine (probable)<\/li><li>Quinupristin (probable)<\/li><li>Rifapentine (probable)<\/li><li>Ritonavir (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sirolimus (established)<\/li><li>Sodium Salicylate (probable)<\/li><li>St John's Wort (probable)<\/li><li>Sulindac (probable)<\/li><li>Tedisamil (established)<\/li><li>Telithromycin (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Tubocurarine (probable)<\/li><li>Valdecoxib (probable)<\/li><li>Vecuronium (probable)<\/li><\/ul>"}]},"5":{"id":"653400-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema (up to 3.7%), Hypotension (1.5% to 3%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (7.3% to 13%)<\/li><li><b>Neurologic:<\/b>Dizziness (3% to 5.9%), Headache (2.2% to 12.1%)<\/li><li><b>Respiratory:<\/b>Pharyngitis (3%), Sinusitis (3%)<\/li><li><b>Other:<\/b>Influenza-like symptoms (3.7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrioventricular block, Myocardial infarction<\/li><li><b>Respiratory:<\/b>Pulmonary edema<\/li><\/ul>"},"6":{"id":"653400-s-6","title":"Drug Name Info","sub":{"0":{"id":"653400-s-6-17","title":"US Trade Names","mono":"<ul><li>Calan<\/li><li>Calan SR<\/li><li>Covera-HS<\/li><li>Isoptin SR<\/li><li>Verelan<\/li><li>Verelan PM<\/li><\/ul>"},"2":{"id":"653400-s-6-19","title":"Class","mono":"<ul><li>Calcium Channel Blocker<\/li><li>Cardiovascular Agent<\/li><li>Phenylalkylamine<\/li><\/ul>"},"3":{"id":"653400-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"653400-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"653400-s-7","title":"Mechanism Of Action","mono":"Verapamil hydrochloride is an L-type calcium channel inhibitor (slow-channel blocker) that selectively blocks the transmembrane influx of calcium ions into arterial smooth muscles including conductile and contractile myocardial cells, without affecting the concentration of serum calcium. Its hypertensive effect is attributed to the reduction of systemic vascular resistance and selective vasodilation of peripheral arteries. Its antianginal effect is related to inhibition of coronary spasm, and relaxation of main coronary artery and coronary arterioles.<br\/>"},"8":{"id":"653400-s-8","title":"Pharmacokinetics","sub":[{"id":"653400-s-8-23","title":"Absorption","mono":"<ul><li>Oral, extended-release capsule and tablet, controlled onset: time to peak concentration, approximately 11 hr<\/li><li>Oral, sustained release caplet: time to peak concentration, 5.21 hr<\/li><li>Bioavailability: (immediate release formulation and sustained release caplet), 13% to 65%<\/li><li>Bioavailability: (hepatic insufficiency), increased compared to healthy patients<\/li><li>Effect of food: (extended release capsule, controlled onset), high fat meal has no effect on extent of absorption and has modest effect on the rate of absorption<\/li><li>Effect of food: (extended release tablet, sustained release caplet), lowers Cmax, delays Tmax, and decreases AUC<\/li><li>Effect of food: (extended release tablet, controlled onset), none<\/li><\/ul>"},{"id":"653400-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 3.8 L\/kg (range 2.4 to 6.8 L\/kg)<\/li><li>Protein binding, Albumin: 86% to 94%<\/li><\/ul>"},{"id":"653400-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: 65% to 80% P450 CYP3A4, CYP1A2, CYP2C8, CYP2C9 and CYP2C18; O-demethylation, N-dealkylation and first-pass metabolism, extensively metabolized<\/li><li>Norverapamil: active l<\/li><\/ul>"},{"id":"653400-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 9% to 16% or more as metabolites<\/li><li>Renal: approximately 70% as metabolites, about 3% to 4% unchanged<\/li><li>Renal clearance: 7.3 to 8.7 mL\/hour\/kg.<\/li><li>Dialyzable: no (hemodialysis)<\/li><\/ul>"},{"id":"653400-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Extended release: 4 hr to 12 hr<\/li><li>Extended release: (age 19 yr to 43 yr): 13 hr<\/li><li>Extended release: (age 65 yr to 80 yr): approximately 20 hr<\/li><li>Norverapamil: 6 to 10 hours.<\/li><li>Liver disease: 14 to 16 hours.<\/li><\/ul>"}]},"9":{"id":"653400-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>do not dilute with sodium lactate injection in polyvinyl chloride (PVC) bags<\/li><li>do not mix with any solution with a pH above 6; precipitation will occur<\/li><li>give bolus over at least 2 minutes under continuous ECG and blood pressure monitoring<\/li><\/ul><\/li><li><b>Oral<\/b><br\/><ul><li>(sustained-release caplet (Calan(R) SR) or tablet (Isoptin(R) SR)) administer with food<\/li><li>(extended-release capsule (Verelan(R) PM) or tablet (Covera-HS(R)) or sustained-release capsule (Verelan(R))) swallow capsule or tablet whole; do not crush or chew<\/li><li>(extended-release capsule (Verelan(R) PM) or sustained-release capsule (Verelan(R))) may sprinkle capsule contents into 1 tablespoon of applesauce, swallow immediately without chewing, and follow with a glass of cool water; do not subdivide contents of capsule<\/li><\/ul><\/li><\/ul>"},"10":{"id":"653400-s-10","title":"Monitoring","mono":"<ul><li>angina: reduction in signs\/symptoms<\/li><li>arrhythmia: ECG and reduction in sign\/symptoms<\/li><li>hypertension: blood pressure weekly during initial period of titration<\/li><li>liver function periodically<\/li><li>ECG; excessive PR interval prolongation in patients with impaired renal or hepatic function<\/li><\/ul>"},"11":{"id":"653400-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Intravenous Solution: 2.5 MG\/ML<\/li><li>Oral Capsule, Extended Release: 100 MG, 120 MG, 180 MG, 200 MG, 240 MG, 300 MG, 360 MG<\/li><li>Oral Tablet: 40 MG, 80 MG, 120 MG<\/li><li>Oral Tablet, Extended Release: 120 MG, 180 MG, 240 MG<\/li><\/ul><\/li><li><b>Calan<\/b><br\/>Oral Tablet: 80 MG, 120 MG<br\/><\/li><li><b>Calan SR<\/b><br\/>Oral Tablet, Extended Release: 120 MG, 180 MG, 240 MG<br\/><\/li><li><b>Covera-HS<\/b><br\/>Oral Tablet, Extended Release, 24 HR: 240 MG<br\/><\/li><li><b>Isoptin SR<\/b><br\/>Oral Tablet, Extended Release: 120 MG, 180 MG, 240 MG<br\/><\/li><li><b>Verelan<\/b><br\/>Oral Capsule, Extended Release: 120 MG, 180 MG, 240 MG, 360 MG<br\/><\/li><li><b>Verelan PM<\/b><br\/>Oral Capsule, Extended Release: 100 MG, 200 MG, 300 MG<br\/><\/li><\/ul>"},"12":{"id":"653400-s-12","title":"Toxicology","sub":[{"id":"653400-s-12-31","title":"Clinical Effects","mono":"<b>VERAPAMIL<\/b><br\/>USES: Verapamil is indicated for the treatment of essential hypertension, angina and in arrhythmias to control ventricular rate. PHARMACOLOGY: Calcium channel blockers are divided into 2 major classes, dihydropyridines and non-dihydropyridines. Verapamil, a phenylalkylamine, is a lipophilic, nondihydropyridine calcium channel blocker. It has selectivity for both vascular and myocardium calcium channels that can produce hypotension, bradycardia and conduction disturbances. Binds to and antagonizes L-type calcium channels located on all types of muscle cells resulting in relaxation of vascular smooth muscle and arterial vasodilation as well as decreased force of cardiac contraction and decreased heart rate and conduction. TOXICOLOGY: Excessive doses cause depression of the SA node (bradycardia) and suppression of conduction through the AV node (heart blocks) as well as decreased contractility. Vasodilatory effects of verapamil overdose are intermediate between those caused by dihydropyridines (eg nifedipine) and benzothiapines (eg diltiazem). EPIDEMIOLOGY: Common overdose, which may result in significant morbidity and mortality. MILD TO MODERATE TOXICITY: Patients may have asymptomatic bradycardia or mild hypotension which may manifest as dizziness, fatigue, and\/or lightheadedness and can cardiac conduction defects (first-degree AV block). SEVERE TOXICITY: Can cause profound bradycardia and dysrhythmias (including complete heart block and asystole), pulmonary edema and hypotension resulting in cardiogenic shock and end-organ dysfunction including lethargy, syncope, altered mental status, seizures, cerebral ischemia, bowel ischemia, hyperkalemia, renal failure, metabolic acidosis, coma, and death.  Hyperglycemia  generally develops in patients with severe poisoning. Rhabdomyolysis may occur in conjunction with acute renal failure follow prolonged hypotension.  ADVERSE EFFECTS: COMMON: Minor gastrointestinal effects, headache, infection, flu-like syndrome and rash have been reported. OTHER EFFECTS: Dizziness, hypotension, bradycardia, congestive heart failure\/pulmonary edema, fatigue and flushing have developed. Cardiac conduction defects (ie, AV blocks, complete heart block) have also occurred with therapy. RARE: Myoclonus and gynecomastia are unusual effects that have been reported.<br\/>"},{"id":"653400-s-12-32","title":"Treatment","mono":"<b>VERAPAMIL<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients who have asymptomatic bradycardia can be admitted and observed with telemetry. Obtain peripheral intravenous access and an ECG. Mild hypotension may only require treatment with intravenous fluid administration. MANAGEMENT OF SEVERE TOXICITY: Patients with bradycardia and hypotension require standard ACLS treatment. Place a central line and consider placement of an arterial line. Standard first line treatment includes atropine for bradycardia although in a serious poisoning it is rarely effective. High dose insulin and dextrose have been effective in animal studies and multiple case reports in patients with hypotension refractory to other modalities, and should be considered early in patients with significant hypotension. Use intravenous calcium in severe poisonings although in these cases, beneficial effects of calcium infusion (calcium chloride is preferred) may be very minimal or short-lived. Repeat bolus doses or a continuous intravenous infusion are often needed. Standard vasopressors should be administered to maintain blood pressure. Lipid emulsion has been successful in animal studies and several case reports of patients with hypotension refractory to other therapies. Intravenous glucagon has been used with variable success. In a patient whose hemodynamic status continues to be refractory despite the treatment described above, extracorporeal membrane oxygenation or cardiopulmonary bypass should be considered. Treat seizures with IV benzodiazepines; barbiturates or propofol may be needed if seizures persist or recur.<\/li><li>Decontamination: PREHOSPITAL: Not recommended because of the potential for abrupt deterioration. HOSPITAL: Because a verapamil overdose can be life-threatening, all significant ingestions should receive activated charcoal. Patients with altered mental status should be intubated prior to administration. Gastric lavage should be considered in patients with recent large ingestions if the airway is protected. Late gastric lavage may be effective following sustained-release products. Whole bowel irrigation should be considered early for patients who can protect their airway or who are intubated who have ingested sustained-release formulations; it can limit absorption from possible concretions. Whole bowel irrigation should NOT be performed in patients who are hemodynamically unstable.<\/li><li>Airway management: Intubate patients with coma, mental status depression or significant hemodynamic instability.<\/li><li>Hypotensive episode: Treat initially with fluids (insert a central venous or pulmonary artery catheter to guide fluid therapy if hypotension persists). Consider inserting an arterial line in patients with refractory hypotension. Intravenous calcium, vasopressors, high dose insulin\/dextrose, intravenous lipid emulsion, and glucagon may all be useful for refractory hypotension. Pacemakers (external or internal), intraaortic balloon pump, and cardiopulmonary bypass have been used in patients refractory to other modalities.<\/li><li>Calcium: Intravenous calcium infusions have been shown to be helpful, although response is often short lived. Optimal dosing is not established; start with an initial IV infusion of about 13 to 25 mEq of calcium (10 to 20 mL of 10% calcium chloride or 30 to 60 mL of 10% calcium gluconate) followed by either repeat boluses every 15 to 20 minutes up to 3 to 4 doses or a continuous infusion starting with 0.5 mEq\/kg\/hr of calcium (0.2 to 0.4 mL\/kg\/hr of 10% calcium chloride or 0.6 to 1.2 mL of 10% calcium gluconate) and titrate as needed. Calcium dosing should be titrated to hemodynamic response rather than serum calcium concentration alone; central venous or pulmonary artery catheters may be useful to guide therapy. Monitor ECG and ionized calcium concentration. Patients with severe overdose have tolerated significant hypercalcemia (up to twice the upper limit of normal) without developing clinical or ECG evidence of hypercalcemia.<\/li><li>Insulin: Administer a bolus of 1 unit\/kg of insulin followed by an infusion of 0.1 to 1 unit\/kg\/hr, titrated to a systolic blood pressure of greater than 90 to 100 mmHg (bradycardia may or may not respond). Reassess every 30 minutes to titrate insulin infusion. Administer dextrose bolus to patients with an initial blood glucose of less than 250 mg\/dL (adults 25 to 50 mL dextrose 50%, children 0.25 g\/kg dextrose 25%). Begin a dextrose infusion of 0.5 g\/kg\/hr in all patients. Monitor blood glucose every 15 to 30 minutes until consistently 100 to 200 mg\/dL for 4 hours, then monitor every hour. Titrate dextrose infusion to maintain blood glucose in the range of 100 to 200 mg\/dL. As the patient improves, insulin resistance abates and dextrose requirements will increase. Supplemental dextrose will be needed for at least several hours after the insulin infusion is discontinued. Administer supplemental potassium initially if patient is hypokalemic (serum potassium less than 2.5 mEq\/L). Monitor serum potassium every 4 hours and supplement as needed to maintain potassium of 2.5 to 2.8 mEq\/L.<\/li><li>Vasopressor: Anecdotal reports suggest that epinephrine, vasopressin, metaraminol, or phenylephrine may occasionally be effective in patients who do not respond to dopamine or norepinephrine.<\/li><li>Fat Emulsion: Lipid emulsion has been successful in animal studies and several case reports of patients with hypotension refractory to other therapies. Administer 1.5 mL\/kg of 20% lipid emulsion over 2 to 3 minutes as an IV bolus, followed by an infusion of 0.25 mL\/kg\/min. If possible, discontinue after 30 to 60 minutes. Longer periods of lipid therapy should be considered if the patient's hemodynamic stability is dependent on continued lipid infusion.<\/li><li>Glucagon: DOSE: ADULT: Optimal dosing in calcium antagonist poisoning is not established. Initially, 3 to 5 mg IV, slowly over 1 to 2 minutes; may repeat treatment with a dose of 4 to 10 mg if there is no hemodynamic improvement within 5 minutes. CHILD: 50 mcg\/kg; repeat doses may be used due to the short half-life of glucagon.<\/li><li>L-Carnitine: L-carnitine may be useful to treat hypotension in the setting of calcium channel blocker overdose. It is not well studied but an animal study and one human case report suggest efficacy. The dose used in the human case report was 6 g IV followed by 1 g IV every 4 hours.<\/li><li>Phosphodiesterase inhibitor: There are case reports where a phosphodiesterase inhibitor (inamrinone, enoximone) appeared to improve blood pressure in patients unresponsive to other modalities.<\/li><li>Monitoring of patient: Serum verapamil concentrations are not readily available and not helpful to guide therapy. Monitor vital signs frequently. Institute continuous cardiac monitoring and obtain serial ECGs. Monitor serum electrolytes, blood glucose, and renal function. In patients with significant hypotension or bradycardia, monitor arterial or venous blood gas, and urine output. Obtain digoxin concentration in patients who also have access to digoxin. Monitor cardiac enzymes in patients with chest pain.<\/li><li>Enhanced elimination procedure: Hemodialysis is likely not of value following a verapamil exposure, because of the high degree of protein binding (90%).<\/li><li>Patient disposition: HOME CRITERIA: According to the AAPCC guidelines, a healthy, asymptomatic adult with a single inadvertent ingestion of verapamil 120 mg or less of immediate-release or a chewed sustained release tablet, or 480 mg or less of a sustained release formulation can be monitored at home. For children, ingestions of less than 2.5 mg\/kg can be monitored at home. OBSERVATION CRITERIA: Symptomatic patients, those with underlying cardiovascular disease, those taking beta blockers or another cardiodepressant drug, and those with deliberate ingestions should be referred to a health care facility for treatment, evaluation and monitoring. According to the AAPCC guidelines, a patient with an inadvertent single ingestion of verapamil greater than 120 mg immediate release or a chewed sustained-release, or greater than 480 mg sustained release formulation should be referred to a healthcare facility. For children, ingestion of greater than 2.5 mg\/kg should be referred to a healthcare facility. Patients should be observed for at least 6 hours after ingestion of immediate release and 18 to 24 hours after ingestion of a sustained release formulation. ADMISSION CRITERIA: Patients who develop signs or symptoms of toxicity should be admitted to an intensive care setting. CONSULT CRITERIA: Consult a poison center or medical toxicologist in cases of severe poisonings or in cases where there is a history of a large exposure.<\/li><\/ul>"},{"id":"653400-s-12-33","title":"Range of Toxicity","mono":"<b>VERAPAMIL<\/b><br\/>TOXICITY: The toxic dose is variable depending on the particular formulation of verapamil. The following doses are considered to be potentially toxic: ADULT DOSE: Greater than 120 mg immediate release or chewed sustained release or greater than 480 mg sustained release formulation. PEDIATRIC DOSE: Greater than 2.5 mg\/kg. Single ingestions of therapeutic adult doses in children have resulted in death.  Patients with underlying cardiovascular disease and the elderly tend to be more susceptible to the cardiac effects.  In general, ingestions of phenylalkylamines (eg, verapamil) are more serious than ingestions of other calcium antagonists (ie, dihydropyridines (nifedipine)). THERAPEUTIC DOSE: ADULT: IMMEDIATE RELEASE: Titrate to desired effect based on indication (range, 240 mg to 480 mg daily), dose should not exceed 480 mg\/day. SUSTAINED RELEASE: Initial therapy: 180 mg daily. EXTENDED RELEASE: Typical dose is 200 mg daily at bedtime; maximum 400 mg daily. PEDIATRIC: Varies by indication. The pediatric maximum single therapeutic dose of verapamil is 2.5 mg\/kg.<br\/>"}]},"13":{"id":"653400-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as this medicine may cause dizziness and light-headedness.<\/li><li>This drug may cause edema, constipation, nausea, and headache.<\/li><li>Patient should watch for signs\/symptoms of hypotension with initial dosing and dose changes.<\/li><li>Advise patient against sudden discontinuation of drug, as this may precipitate hypertensive rebound\/crisis.<\/li><li>Patient should not drink alcohol while taking this drug.<\/li><\/ul>"}}}